Zelgen: The Phase III clinical trial of Hydrochloride Gikaxitin Tablets for the treatment of active ankylosing spondylitis has reached the primary efficacy endpoint
I'm PortAI, I can summarize articles.
Zelgen announced that its self-developed Jikaxitinib hydrochloride tablets achieved the primary efficacy endpoint in the Phase III clinical trial for the treatment of active ankylosing spondylitis, with statistical significance (p
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments